Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts
This study introduces a unique mouse model at a critical point in the evolution of treatment paradigms for patients with hepatocellular carcinoma (HCC). Immunotherapies have become the first-line treatment for advanced HCC; however, response rates remain low with no clear predictors of response to guide patient selection. In this context, animal models that recapitulate human disease are greatly needed. Leveraging xenograft tumors derived from patients with unresectable HCCs and a commercially available immunodeficient mouse strain that expresses human GM-CSF and IL-3, we demonstrate a novel but accessible approach for modeling the HCC tumor microenvironment.
Authors
- George McClung
- David J. Tischfield (ORCID: https://orcid.org/0000-0002-1338-2517)
- Emma E. Furth (ORCID: https://orcid.org/0000-0002-9309-985X)
- John Dozier Gordan (ORCID: https://orcid.org/0000-0001-8997-5725)
- Jing Jiao
- Jennifer Crainic
- Stephen J. Hunt (ORCID: https://orcid.org/0000-0002-6400-4321)
- G. Nadolski (ORCID: https://orcid.org/0000-0003-4721-8288)
- Wuyan Li
- T. Gade (ORCID: https://orcid.org/0000-0001-8783-0661)
- Kelley Weinfurtner (ORCID: https://orcid.org/0000-0003-1506-232X)
- David E. Kaplan (ORCID: https://orcid.org/0000-0002-3839-336X)
- Erena Tuzneen Supan
Institutions
- University of California, San Francisco (US)
- Fred Hutch Cancer Center (US)
- Philadelphia VA Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JHEP Reports
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1016/j.jhepr.2024.101264
- Citations
- 2
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- U.S. Department of Defense